PubMed:12626389 JSONTXT

{"project":"sentences","denotations":[{"id":"TextSentencer_T1","span":{"begin":0,"end":141},"obj":"Sentence"},{"id":"TextSentencer_T2","span":{"begin":142,"end":351},"obj":"Sentence"},{"id":"TextSentencer_T3","span":{"begin":352,"end":452},"obj":"Sentence"},{"id":"TextSentencer_T4","span":{"begin":453,"end":676},"obj":"Sentence"},{"id":"TextSentencer_T5","span":{"begin":677,"end":889},"obj":"Sentence"},{"id":"TextSentencer_T6","span":{"begin":890,"end":1228},"obj":"Sentence"},{"id":"T1","span":{"begin":0,"end":141},"obj":"Sentence"},{"id":"T2","span":{"begin":142,"end":351},"obj":"Sentence"},{"id":"T3","span":{"begin":352,"end":452},"obj":"Sentence"},{"id":"T4","span":{"begin":453,"end":676},"obj":"Sentence"},{"id":"T5","span":{"begin":677,"end":889},"obj":"Sentence"},{"id":"T6","span":{"begin":890,"end":1228},"obj":"Sentence"},{"id":"T1","span":{"begin":0,"end":141},"obj":"Sentence"},{"id":"T2","span":{"begin":142,"end":351},"obj":"Sentence"},{"id":"T3","span":{"begin":352,"end":452},"obj":"Sentence"},{"id":"T4","span":{"begin":453,"end":676},"obj":"Sentence"},{"id":"T5","span":{"begin":677,"end":889},"obj":"Sentence"},{"id":"T6","span":{"begin":890,"end":1228},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Increased fucosylation and reduced branching of serum glycoprotein N-glycans in all known subtypes of congenital disorder of glycosylation I.\nThe N-glycans present on the total mixture of serum glycoproteins (serum N-glycome) were analyzed in 24 subjects with congenital disorder of glycosylation type I (CDG-I) and 7 healthy, age-matched individuals. No new N-glycan structures were observed in the sera of CDG-I patients as compared with normal sera. However, we observed in all subtypes a significantly increased degree of core alpha-1,6-fucosylation of the biantennary glycans as compared to normal, as well as a significant decrease in the amount of triantennary glycans. These serum N-glycome changes appear to be a milder manifestation of some of the changes observed in adult liver cirrhosis patients, which is compatible with the reported steatosis and fibrosis in CDG-I patients. In the CDG-Ia subgroup, the extent of the serum N-glycome changes correlates with the aberration of the serum transferrin isoelectric focusing pattern, which measures the severity of the lack of entire N-glycan chains (primary consequence of CDG-I) in the liver and is the standard diagnostic test for this category of inherited diseases."}

{"project":"Glycosmos6-MAT","denotations":[{"id":"T1","span":{"begin":784,"end":789},"obj":"http://purl.obolibrary.org/obo/MAT_0000097"},{"id":"T2","span":{"begin":1146,"end":1151},"obj":"http://purl.obolibrary.org/obo/MAT_0000097"}],"text":"Increased fucosylation and reduced branching of serum glycoprotein N-glycans in all known subtypes of congenital disorder of glycosylation I.\nThe N-glycans present on the total mixture of serum glycoproteins (serum N-glycome) were analyzed in 24 subjects with congenital disorder of glycosylation type I (CDG-I) and 7 healthy, age-matched individuals. No new N-glycan structures were observed in the sera of CDG-I patients as compared with normal sera. However, we observed in all subtypes a significantly increased degree of core alpha-1,6-fucosylation of the biantennary glycans as compared to normal, as well as a significant decrease in the amount of triantennary glycans. These serum N-glycome changes appear to be a milder manifestation of some of the changes observed in adult liver cirrhosis patients, which is compatible with the reported steatosis and fibrosis in CDG-I patients. In the CDG-Ia subgroup, the extent of the serum N-glycome changes correlates with the aberration of the serum transferrin isoelectric focusing pattern, which measures the severity of the lack of entire N-glycan chains (primary consequence of CDG-I) in the liver and is the standard diagnostic test for this category of inherited diseases."}

{"project":"GlycoBiology-GDGDB","denotations":[{"id":"_T1","span":{"begin":102,"end":138},"obj":"http://acgg.asia/db/diseases/gdgdb?con_ui=CON00360"},{"id":"_T2","span":{"begin":102,"end":138},"obj":"http://acgg.asia/db/diseases/gdgdb?con_ui=CON00354"},{"id":"_T3","span":{"begin":102,"end":138},"obj":"http://acgg.asia/db/diseases/gdgdb?con_ui=CON00627"},{"id":"_T4","span":{"begin":102,"end":140},"obj":"http://acgg.asia/db/diseases/gdgdb?con_ui=CON00355"},{"id":"_T5","span":{"begin":102,"end":140},"obj":"http://acgg.asia/db/diseases/gdgdb?con_ui=CON00365"},{"id":"_T6","span":{"begin":102,"end":140},"obj":"http://acgg.asia/db/diseases/gdgdb?con_ui=CON00367"},{"id":"_T7","span":{"begin":102,"end":140},"obj":"http://acgg.asia/db/diseases/gdgdb?con_ui=CON00364"},{"id":"_T8","span":{"begin":102,"end":140},"obj":"http://acgg.asia/db/diseases/gdgdb?con_ui=CON00343"},{"id":"_T9","span":{"begin":102,"end":140},"obj":"http://acgg.asia/db/diseases/gdgdb?con_ui=CON00363"},{"id":"_T10","span":{"begin":102,"end":140},"obj":"http://acgg.asia/db/diseases/gdgdb?con_ui=CON00344"},{"id":"_T11","span":{"begin":102,"end":140},"obj":"http://acgg.asia/db/diseases/gdgdb?con_ui=CON00362"},{"id":"_T12","span":{"begin":102,"end":140},"obj":"http://acgg.asia/db/diseases/gdgdb?con_ui=CON00345"},{"id":"_T13","span":{"begin":102,"end":140},"obj":"http://acgg.asia/db/diseases/gdgdb?con_ui=CON00361"},{"id":"_T14","span":{"begin":102,"end":140},"obj":"http://acgg.asia/db/diseases/gdgdb?con_ui=CON00346"},{"id":"_T15","span":{"begin":102,"end":140},"obj":"http://acgg.asia/db/diseases/gdgdb?con_ui=CON00359"},{"id":"_T16","span":{"begin":102,"end":140},"obj":"http://acgg.asia/db/diseases/gdgdb?con_ui=CON00358"},{"id":"_T17","span":{"begin":102,"end":140},"obj":"http://acgg.asia/db/diseases/gdgdb?con_ui=CON00626"},{"id":"_T18","span":{"begin":102,"end":140},"obj":"http://acgg.asia/db/diseases/gdgdb?con_ui=CON00625"},{"id":"_T19","span":{"begin":102,"end":140},"obj":"http://acgg.asia/db/diseases/gdgdb?con_ui=CON00349"},{"id":"_T20","span":{"begin":102,"end":140},"obj":"http://acgg.asia/db/diseases/gdgdb?con_ui=CON00624"},{"id":"_T21","span":{"begin":102,"end":140},"obj":"http://acgg.asia/db/diseases/gdgdb?con_ui=CON00350"},{"id":"_T22","span":{"begin":102,"end":140},"obj":"http://acgg.asia/db/diseases/gdgdb?con_ui=CON00623"},{"id":"_T23","span":{"begin":102,"end":140},"obj":"http://acgg.asia/db/diseases/gdgdb?con_ui=CON00351"},{"id":"_T24","span":{"begin":102,"end":140},"obj":"http://acgg.asia/db/diseases/gdgdb?con_ui=CON00622"},{"id":"_T25","span":{"begin":102,"end":140},"obj":"http://acgg.asia/db/diseases/gdgdb?con_ui=CON00352"},{"id":"_T26","span":{"begin":102,"end":140},"obj":"http://acgg.asia/db/diseases/gdgdb?con_ui=CON00621"},{"id":"_T27","span":{"begin":102,"end":140},"obj":"http://acgg.asia/db/diseases/gdgdb?con_ui=CON00353"},{"id":"_T28","span":{"begin":102,"end":140},"obj":"http://acgg.asia/db/diseases/gdgdb?con_ui=CON00620"},{"id":"_T29","span":{"begin":102,"end":140},"obj":"http://acgg.asia/db/diseases/gdgdb?con_ui=CON00348"},{"id":"_T30","span":{"begin":102,"end":140},"obj":"http://acgg.asia/db/diseases/gdgdb?con_ui=CON00356"},{"id":"_T31","span":{"begin":102,"end":140},"obj":"http://acgg.asia/db/diseases/gdgdb?con_ui=CON00347"},{"id":"_T32","span":{"begin":260,"end":301},"obj":"http://acgg.asia/db/diseases/gdgdb?con_ui=CON00347"},{"id":"_T33","span":{"begin":260,"end":301},"obj":"http://acgg.asia/db/diseases/gdgdb?con_ui=CON00362"},{"id":"_T34","span":{"begin":260,"end":303},"obj":"http://acgg.asia/db/diseases/gdgdb?con_ui=CON00355"},{"id":"_T35","span":{"begin":260,"end":303},"obj":"http://acgg.asia/db/diseases/gdgdb?con_ui=CON00353"},{"id":"_T36","span":{"begin":260,"end":303},"obj":"http://acgg.asia/db/diseases/gdgdb?con_ui=CON00620"},{"id":"_T37","span":{"begin":260,"end":303},"obj":"http://acgg.asia/db/diseases/gdgdb?con_ui=CON00352"},{"id":"_T38","span":{"begin":260,"end":303},"obj":"http://acgg.asia/db/diseases/gdgdb?con_ui=CON00621"},{"id":"_T39","span":{"begin":260,"end":303},"obj":"http://acgg.asia/db/diseases/gdgdb?con_ui=CON00351"},{"id":"_T40","span":{"begin":260,"end":303},"obj":"http://acgg.asia/db/diseases/gdgdb?con_ui=CON00622"},{"id":"_T41","span":{"begin":260,"end":303},"obj":"http://acgg.asia/db/diseases/gdgdb?con_ui=CON00350"},{"id":"_T42","span":{"begin":260,"end":303},"obj":"http://acgg.asia/db/diseases/gdgdb?con_ui=CON00623"},{"id":"_T43","span":{"begin":260,"end":303},"obj":"http://acgg.asia/db/diseases/gdgdb?con_ui=CON00349"},{"id":"_T44","span":{"begin":260,"end":303},"obj":"http://acgg.asia/db/diseases/gdgdb?con_ui=CON00624"},{"id":"_T45","span":{"begin":260,"end":303},"obj":"http://acgg.asia/db/diseases/gdgdb?con_ui=CON00348"},{"id":"_T46","span":{"begin":260,"end":303},"obj":"http://acgg.asia/db/diseases/gdgdb?con_ui=CON00625"},{"id":"_T47","span":{"begin":260,"end":303},"obj":"http://acgg.asia/db/diseases/gdgdb?con_ui=CON00356"},{"id":"_T48","span":{"begin":260,"end":303},"obj":"http://acgg.asia/db/diseases/gdgdb?con_ui=CON00358"},{"id":"_T49","span":{"begin":260,"end":303},"obj":"http://acgg.asia/db/diseases/gdgdb?con_ui=CON00346"},{"id":"_T50","span":{"begin":260,"end":303},"obj":"http://acgg.asia/db/diseases/gdgdb?con_ui=CON00359"},{"id":"_T51","span":{"begin":260,"end":303},"obj":"http://acgg.asia/db/diseases/gdgdb?con_ui=CON00345"},{"id":"_T52","span":{"begin":260,"end":303},"obj":"http://acgg.asia/db/diseases/gdgdb?con_ui=CON00361"},{"id":"_T53","span":{"begin":260,"end":303},"obj":"http://acgg.asia/db/diseases/gdgdb?con_ui=CON00344"},{"id":"_T54","span":{"begin":260,"end":303},"obj":"http://acgg.asia/db/diseases/gdgdb?con_ui=CON00354"},{"id":"_T55","span":{"begin":260,"end":303},"obj":"http://acgg.asia/db/diseases/gdgdb?con_ui=CON00343"},{"id":"_T56","span":{"begin":260,"end":303},"obj":"http://acgg.asia/db/diseases/gdgdb?con_ui=CON00363"},{"id":"_T57","span":{"begin":260,"end":303},"obj":"http://acgg.asia/db/diseases/gdgdb?con_ui=CON00626"},{"id":"_T58","span":{"begin":260,"end":303},"obj":"http://acgg.asia/db/diseases/gdgdb?con_ui=CON00364"},{"id":"_T59","span":{"begin":260,"end":303},"obj":"http://acgg.asia/db/diseases/gdgdb?con_ui=CON00627"},{"id":"_T60","span":{"begin":260,"end":303},"obj":"http://acgg.asia/db/diseases/gdgdb?con_ui=CON00365"},{"id":"_T61","span":{"begin":260,"end":303},"obj":"http://acgg.asia/db/diseases/gdgdb?con_ui=CON00367"},{"id":"_T62","span":{"begin":260,"end":303},"obj":"http://acgg.asia/db/diseases/gdgdb?con_ui=CON00360"},{"id":"_T63","span":{"begin":305,"end":310},"obj":"http://acgg.asia/db/diseases/gdgdb?con_ui=CON00351"},{"id":"_T64","span":{"begin":408,"end":413},"obj":"http://acgg.asia/db/diseases/gdgdb?con_ui=CON00351"},{"id":"_T65","span":{"begin":874,"end":879},"obj":"http://acgg.asia/db/diseases/gdgdb?con_ui=CON00351"},{"id":"_T66","span":{"begin":897,"end":903},"obj":"http://acgg.asia/db/diseases/gdgdb?con_ui=CON00358"},{"id":"_T67","span":{"begin":897,"end":903},"obj":"http://acgg.asia/db/diseases/gdgdb?con_ui=CON00343"},{"id":"_T68","span":{"begin":1132,"end":1137},"obj":"http://acgg.asia/db/diseases/gdgdb?con_ui=CON00351"},{"id":"_T69","span":{"begin":1132,"end":1141},"obj":"http://acgg.asia/db/diseases/gdgdb?con_ui=CON00356"}],"text":"Increased fucosylation and reduced branching of serum glycoprotein N-glycans in all known subtypes of congenital disorder of glycosylation I.\nThe N-glycans present on the total mixture of serum glycoproteins (serum N-glycome) were analyzed in 24 subjects with congenital disorder of glycosylation type I (CDG-I) and 7 healthy, age-matched individuals. No new N-glycan structures were observed in the sera of CDG-I patients as compared with normal sera. However, we observed in all subtypes a significantly increased degree of core alpha-1,6-fucosylation of the biantennary glycans as compared to normal, as well as a significant decrease in the amount of triantennary glycans. These serum N-glycome changes appear to be a milder manifestation of some of the changes observed in adult liver cirrhosis patients, which is compatible with the reported steatosis and fibrosis in CDG-I patients. In the CDG-Ia subgroup, the extent of the serum N-glycome changes correlates with the aberration of the serum transferrin isoelectric focusing pattern, which measures the severity of the lack of entire N-glycan chains (primary consequence of CDG-I) in the liver and is the standard diagnostic test for this category of inherited diseases."}

{"project":"GlycoBiology-FMA","denotations":[{"id":"_T1","span":{"begin":35,"end":44},"obj":"FMAID:226027"},{"id":"_T2","span":{"begin":35,"end":44},"obj":"FMAID:226028"},{"id":"_T3","span":{"begin":48,"end":53},"obj":"FMAID:167330"},{"id":"_T4","span":{"begin":54,"end":66},"obj":"FMAID:167256"},{"id":"_T5","span":{"begin":54,"end":66},"obj":"FMAID:62925"},{"id":"_T6","span":{"begin":188,"end":193},"obj":"FMAID:167330"},{"id":"_T7","span":{"begin":194,"end":207},"obj":"FMAID:62925"},{"id":"_T8","span":{"begin":194,"end":207},"obj":"FMAID:167256"},{"id":"_T9","span":{"begin":209,"end":214},"obj":"FMAID:167330"},{"id":"_T10","span":{"begin":327,"end":330},"obj":"FMAID:276692"},{"id":"_T11","span":{"begin":683,"end":688},"obj":"FMAID:167330"},{"id":"_T12","span":{"begin":784,"end":789},"obj":"FMAID:7197"},{"id":"_T13","span":{"begin":784,"end":789},"obj":"FMAID:93672"},{"id":"_T14","span":{"begin":932,"end":937},"obj":"FMAID:167330"},{"id":"_T15","span":{"begin":994,"end":999},"obj":"FMAID:167330"},{"id":"_T16","span":{"begin":1146,"end":1151},"obj":"FMAID:7197"},{"id":"_T17","span":{"begin":1146,"end":1151},"obj":"FMAID:93672"},{"id":"_T18","span":{"begin":1183,"end":1187},"obj":"FMAID:178661"}],"namespaces":[{"prefix":"FMAID","uri":"http://purl.org/sig/ont/fma/fma"}],"text":"Increased fucosylation and reduced branching of serum glycoprotein N-glycans in all known subtypes of congenital disorder of glycosylation I.\nThe N-glycans present on the total mixture of serum glycoproteins (serum N-glycome) were analyzed in 24 subjects with congenital disorder of glycosylation type I (CDG-I) and 7 healthy, age-matched individuals. No new N-glycan structures were observed in the sera of CDG-I patients as compared with normal sera. However, we observed in all subtypes a significantly increased degree of core alpha-1,6-fucosylation of the biantennary glycans as compared to normal, as well as a significant decrease in the amount of triantennary glycans. These serum N-glycome changes appear to be a milder manifestation of some of the changes observed in adult liver cirrhosis patients, which is compatible with the reported steatosis and fibrosis in CDG-I patients. In the CDG-Ia subgroup, the extent of the serum N-glycome changes correlates with the aberration of the serum transferrin isoelectric focusing pattern, which measures the severity of the lack of entire N-glycan chains (primary consequence of CDG-I) in the liver and is the standard diagnostic test for this category of inherited diseases."}

{"project":"uniprot-human","denotations":[{"id":"T1","span":{"begin":1000,"end":1011},"obj":"http://www.uniprot.org/uniprot/P02787"}],"text":"Increased fucosylation and reduced branching of serum glycoprotein N-glycans in all known subtypes of congenital disorder of glycosylation I.\nThe N-glycans present on the total mixture of serum glycoproteins (serum N-glycome) were analyzed in 24 subjects with congenital disorder of glycosylation type I (CDG-I) and 7 healthy, age-matched individuals. No new N-glycan structures were observed in the sera of CDG-I patients as compared with normal sera. However, we observed in all subtypes a significantly increased degree of core alpha-1,6-fucosylation of the biantennary glycans as compared to normal, as well as a significant decrease in the amount of triantennary glycans. These serum N-glycome changes appear to be a milder manifestation of some of the changes observed in adult liver cirrhosis patients, which is compatible with the reported steatosis and fibrosis in CDG-I patients. In the CDG-Ia subgroup, the extent of the serum N-glycome changes correlates with the aberration of the serum transferrin isoelectric focusing pattern, which measures the severity of the lack of entire N-glycan chains (primary consequence of CDG-I) in the liver and is the standard diagnostic test for this category of inherited diseases."}

{"project":"uniprot-mouse","denotations":[{"id":"T1","span":{"begin":1000,"end":1011},"obj":"http://www.uniprot.org/uniprot/Q63915"}],"text":"Increased fucosylation and reduced branching of serum glycoprotein N-glycans in all known subtypes of congenital disorder of glycosylation I.\nThe N-glycans present on the total mixture of serum glycoproteins (serum N-glycome) were analyzed in 24 subjects with congenital disorder of glycosylation type I (CDG-I) and 7 healthy, age-matched individuals. No new N-glycan structures were observed in the sera of CDG-I patients as compared with normal sera. However, we observed in all subtypes a significantly increased degree of core alpha-1,6-fucosylation of the biantennary glycans as compared to normal, as well as a significant decrease in the amount of triantennary glycans. These serum N-glycome changes appear to be a milder manifestation of some of the changes observed in adult liver cirrhosis patients, which is compatible with the reported steatosis and fibrosis in CDG-I patients. In the CDG-Ia subgroup, the extent of the serum N-glycome changes correlates with the aberration of the serum transferrin isoelectric focusing pattern, which measures the severity of the lack of entire N-glycan chains (primary consequence of CDG-I) in the liver and is the standard diagnostic test for this category of inherited diseases."}

{"project":"GO-BP","denotations":[{"id":"T1","span":{"begin":10,"end":22},"obj":"http://purl.obolibrary.org/obo/GO_0036065"},{"id":"T2","span":{"begin":541,"end":553},"obj":"http://purl.obolibrary.org/obo/GO_0036065"},{"id":"T3","span":{"begin":125,"end":138},"obj":"http://purl.obolibrary.org/obo/GO_0070085"},{"id":"T4","span":{"begin":283,"end":296},"obj":"http://purl.obolibrary.org/obo/GO_0070085"},{"id":"T5","span":{"begin":327,"end":330},"obj":"http://purl.obolibrary.org/obo/GO_0007568"},{"id":"T6","span":{"begin":400,"end":404},"obj":"http://purl.obolibrary.org/obo/GO_0004617"},{"id":"T7","span":{"begin":447,"end":451},"obj":"http://purl.obolibrary.org/obo/GO_0004617"}],"text":"Increased fucosylation and reduced branching of serum glycoprotein N-glycans in all known subtypes of congenital disorder of glycosylation I.\nThe N-glycans present on the total mixture of serum glycoproteins (serum N-glycome) were analyzed in 24 subjects with congenital disorder of glycosylation type I (CDG-I) and 7 healthy, age-matched individuals. No new N-glycan structures were observed in the sera of CDG-I patients as compared with normal sera. However, we observed in all subtypes a significantly increased degree of core alpha-1,6-fucosylation of the biantennary glycans as compared to normal, as well as a significant decrease in the amount of triantennary glycans. These serum N-glycome changes appear to be a milder manifestation of some of the changes observed in adult liver cirrhosis patients, which is compatible with the reported steatosis and fibrosis in CDG-I patients. In the CDG-Ia subgroup, the extent of the serum N-glycome changes correlates with the aberration of the serum transferrin isoelectric focusing pattern, which measures the severity of the lack of entire N-glycan chains (primary consequence of CDG-I) in the liver and is the standard diagnostic test for this category of inherited diseases."}

{"project":"GO-CC","denotations":[{"id":"T1","span":{"begin":526,"end":530},"obj":"http://purl.obolibrary.org/obo/GO_0019013"}],"text":"Increased fucosylation and reduced branching of serum glycoprotein N-glycans in all known subtypes of congenital disorder of glycosylation I.\nThe N-glycans present on the total mixture of serum glycoproteins (serum N-glycome) were analyzed in 24 subjects with congenital disorder of glycosylation type I (CDG-I) and 7 healthy, age-matched individuals. No new N-glycan structures were observed in the sera of CDG-I patients as compared with normal sera. However, we observed in all subtypes a significantly increased degree of core alpha-1,6-fucosylation of the biantennary glycans as compared to normal, as well as a significant decrease in the amount of triantennary glycans. These serum N-glycome changes appear to be a milder manifestation of some of the changes observed in adult liver cirrhosis patients, which is compatible with the reported steatosis and fibrosis in CDG-I patients. In the CDG-Ia subgroup, the extent of the serum N-glycome changes correlates with the aberration of the serum transferrin isoelectric focusing pattern, which measures the severity of the lack of entire N-glycan chains (primary consequence of CDG-I) in the liver and is the standard diagnostic test for this category of inherited diseases."}

{"project":"UBERON-AE","denotations":[{"id":"T1","span":{"begin":48,"end":53},"obj":"http://purl.obolibrary.org/obo/UBERON_0001977"},{"id":"T2","span":{"begin":188,"end":193},"obj":"http://purl.obolibrary.org/obo/UBERON_0001977"},{"id":"T3","span":{"begin":209,"end":214},"obj":"http://purl.obolibrary.org/obo/UBERON_0001977"},{"id":"T4","span":{"begin":683,"end":688},"obj":"http://purl.obolibrary.org/obo/UBERON_0001977"},{"id":"T5","span":{"begin":932,"end":937},"obj":"http://purl.obolibrary.org/obo/UBERON_0001977"},{"id":"T6","span":{"begin":994,"end":999},"obj":"http://purl.obolibrary.org/obo/UBERON_0001977"},{"id":"T7","span":{"begin":784,"end":789},"obj":"http://purl.obolibrary.org/obo/UBERON_0002107"},{"id":"T8","span":{"begin":1146,"end":1151},"obj":"http://purl.obolibrary.org/obo/UBERON_0002107"}],"text":"Increased fucosylation and reduced branching of serum glycoprotein N-glycans in all known subtypes of congenital disorder of glycosylation I.\nThe N-glycans present on the total mixture of serum glycoproteins (serum N-glycome) were analyzed in 24 subjects with congenital disorder of glycosylation type I (CDG-I) and 7 healthy, age-matched individuals. No new N-glycan structures were observed in the sera of CDG-I patients as compared with normal sera. However, we observed in all subtypes a significantly increased degree of core alpha-1,6-fucosylation of the biantennary glycans as compared to normal, as well as a significant decrease in the amount of triantennary glycans. These serum N-glycome changes appear to be a milder manifestation of some of the changes observed in adult liver cirrhosis patients, which is compatible with the reported steatosis and fibrosis in CDG-I patients. In the CDG-Ia subgroup, the extent of the serum N-glycome changes correlates with the aberration of the serum transferrin isoelectric focusing pattern, which measures the severity of the lack of entire N-glycan chains (primary consequence of CDG-I) in the liver and is the standard diagnostic test for this category of inherited diseases."}

{"project":"EDAM-topics","denotations":[{"id":"T1","span":{"begin":1219,"end":1227},"obj":"http://edamontology.org/topic_0634"}],"text":"Increased fucosylation and reduced branching of serum glycoprotein N-glycans in all known subtypes of congenital disorder of glycosylation I.\nThe N-glycans present on the total mixture of serum glycoproteins (serum N-glycome) were analyzed in 24 subjects with congenital disorder of glycosylation type I (CDG-I) and 7 healthy, age-matched individuals. No new N-glycan structures were observed in the sera of CDG-I patients as compared with normal sera. However, we observed in all subtypes a significantly increased degree of core alpha-1,6-fucosylation of the biantennary glycans as compared to normal, as well as a significant decrease in the amount of triantennary glycans. These serum N-glycome changes appear to be a milder manifestation of some of the changes observed in adult liver cirrhosis patients, which is compatible with the reported steatosis and fibrosis in CDG-I patients. In the CDG-Ia subgroup, the extent of the serum N-glycome changes correlates with the aberration of the serum transferrin isoelectric focusing pattern, which measures the severity of the lack of entire N-glycan chains (primary consequence of CDG-I) in the liver and is the standard diagnostic test for this category of inherited diseases."}

{"project":"EDAM-DFO","denotations":[{"id":"T1","span":{"begin":331,"end":338},"obj":"http://edamontology.org/format_1990"},{"id":"T2","span":{"begin":368,"end":378},"obj":"http://edamontology.org/data_0883"},{"id":"T3","span":{"begin":440,"end":446},"obj":"http://edamontology.org/operation_3435"},{"id":"T4","span":{"begin":596,"end":602},"obj":"http://edamontology.org/operation_3435"},{"id":"T5","span":{"begin":839,"end":847},"obj":"http://edamontology.org/data_2048"},{"id":"T6","span":{"begin":956,"end":966},"obj":"http://edamontology.org/operation_3465"},{"id":"T7","span":{"begin":1048,"end":1056},"obj":"http://edamontology.org/data_3108"},{"id":"T8","span":{"begin":1163,"end":1171},"obj":"http://edamontology.org/operation_3435"}],"text":"Increased fucosylation and reduced branching of serum glycoprotein N-glycans in all known subtypes of congenital disorder of glycosylation I.\nThe N-glycans present on the total mixture of serum glycoproteins (serum N-glycome) were analyzed in 24 subjects with congenital disorder of glycosylation type I (CDG-I) and 7 healthy, age-matched individuals. No new N-glycan structures were observed in the sera of CDG-I patients as compared with normal sera. However, we observed in all subtypes a significantly increased degree of core alpha-1,6-fucosylation of the biantennary glycans as compared to normal, as well as a significant decrease in the amount of triantennary glycans. These serum N-glycome changes appear to be a milder manifestation of some of the changes observed in adult liver cirrhosis patients, which is compatible with the reported steatosis and fibrosis in CDG-I patients. In the CDG-Ia subgroup, the extent of the serum N-glycome changes correlates with the aberration of the serum transferrin isoelectric focusing pattern, which measures the severity of the lack of entire N-glycan chains (primary consequence of CDG-I) in the liver and is the standard diagnostic test for this category of inherited diseases."}

{"project":"GlycoBiology-MAT","denotations":[{"id":"T1","span":{"begin":784,"end":789},"obj":"http://purl.obolibrary.org/obo/MAT_0000097"},{"id":"T2","span":{"begin":1146,"end":1151},"obj":"http://purl.obolibrary.org/obo/MAT_0000097"}],"text":"Increased fucosylation and reduced branching of serum glycoprotein N-glycans in all known subtypes of congenital disorder of glycosylation I.\nThe N-glycans present on the total mixture of serum glycoproteins (serum N-glycome) were analyzed in 24 subjects with congenital disorder of glycosylation type I (CDG-I) and 7 healthy, age-matched individuals. No new N-glycan structures were observed in the sera of CDG-I patients as compared with normal sera. However, we observed in all subtypes a significantly increased degree of core alpha-1,6-fucosylation of the biantennary glycans as compared to normal, as well as a significant decrease in the amount of triantennary glycans. These serum N-glycome changes appear to be a milder manifestation of some of the changes observed in adult liver cirrhosis patients, which is compatible with the reported steatosis and fibrosis in CDG-I patients. In the CDG-Ia subgroup, the extent of the serum N-glycome changes correlates with the aberration of the serum transferrin isoelectric focusing pattern, which measures the severity of the lack of entire N-glycan chains (primary consequence of CDG-I) in the liver and is the standard diagnostic test for this category of inherited diseases."}

{"project":"GlycoBiology-Motifs","denotations":[{"id":"T1","span":{"begin":67,"end":76},"obj":"http://rdf.glycoinfo.org/glycan/G00027MO"},{"id":"T2","span":{"begin":146,"end":155},"obj":"http://rdf.glycoinfo.org/glycan/G00027MO"},{"id":"T3","span":{"begin":359,"end":367},"obj":"http://rdf.glycoinfo.org/glycan/G00027MO"},{"id":"T4","span":{"begin":1092,"end":1100},"obj":"http://rdf.glycoinfo.org/glycan/G00027MO"}],"text":"Increased fucosylation and reduced branching of serum glycoprotein N-glycans in all known subtypes of congenital disorder of glycosylation I.\nThe N-glycans present on the total mixture of serum glycoproteins (serum N-glycome) were analyzed in 24 subjects with congenital disorder of glycosylation type I (CDG-I) and 7 healthy, age-matched individuals. No new N-glycan structures were observed in the sera of CDG-I patients as compared with normal sera. However, we observed in all subtypes a significantly increased degree of core alpha-1,6-fucosylation of the biantennary glycans as compared to normal, as well as a significant decrease in the amount of triantennary glycans. These serum N-glycome changes appear to be a milder manifestation of some of the changes observed in adult liver cirrhosis patients, which is compatible with the reported steatosis and fibrosis in CDG-I patients. In the CDG-Ia subgroup, the extent of the serum N-glycome changes correlates with the aberration of the serum transferrin isoelectric focusing pattern, which measures the severity of the lack of entire N-glycan chains (primary consequence of CDG-I) in the liver and is the standard diagnostic test for this category of inherited diseases."}

{"project":"GlyTouCan-IUPAC","denotations":[{"id":"GlycanIUPAC_T1","span":{"begin":80,"end":83},"obj":"\"http://rdf.glycoinfo.org/glycan/G41652MJ\""},{"id":"GlycanIUPAC_T2","span":{"begin":477,"end":480},"obj":"\"http://rdf.glycoinfo.org/glycan/G41652MJ\""},{"id":"GlycanIUPAC_T3","span":{"begin":80,"end":83},"obj":"\"http://rdf.glycoinfo.org/glycan/G20761YC\""},{"id":"GlycanIUPAC_T4","span":{"begin":477,"end":480},"obj":"\"http://rdf.glycoinfo.org/glycan/G20761YC\""},{"id":"GlycanIUPAC_T5","span":{"begin":80,"end":83},"obj":"\"http://rdf.glycoinfo.org/glycan/G19807HM\""},{"id":"GlycanIUPAC_T6","span":{"begin":477,"end":480},"obj":"\"http://rdf.glycoinfo.org/glycan/G19807HM\""},{"id":"GlycanIUPAC_T7","span":{"begin":80,"end":83},"obj":"\"http://rdf.glycoinfo.org/glycan/G20351TE\""},{"id":"GlycanIUPAC_T8","span":{"begin":477,"end":480},"obj":"\"http://rdf.glycoinfo.org/glycan/G20351TE\""},{"id":"GlycanIUPAC_T9","span":{"begin":80,"end":83},"obj":"\"http://rdf.glycoinfo.org/glycan/G71957MR\""},{"id":"GlycanIUPAC_T10","span":{"begin":477,"end":480},"obj":"\"http://rdf.glycoinfo.org/glycan/G71957MR\""},{"id":"GlycanIUPAC_T11","span":{"begin":80,"end":83},"obj":"\"http://rdf.glycoinfo.org/glycan/G59040AE\""},{"id":"GlycanIUPAC_T12","span":{"begin":477,"end":480},"obj":"\"http://rdf.glycoinfo.org/glycan/G59040AE\""},{"id":"GlycanIUPAC_T13","span":{"begin":80,"end":83},"obj":"\"http://rdf.glycoinfo.org/glycan/G14987PW\""},{"id":"GlycanIUPAC_T14","span":{"begin":477,"end":480},"obj":"\"http://rdf.glycoinfo.org/glycan/G14987PW\""},{"id":"GlycanIUPAC_T15","span":{"begin":80,"end":83},"obj":"\"http://rdf.glycoinfo.org/glycan/G95064PC\""},{"id":"GlycanIUPAC_T16","span":{"begin":477,"end":480},"obj":"\"http://rdf.glycoinfo.org/glycan/G95064PC\""},{"id":"GlycanIUPAC_T17","span":{"begin":80,"end":83},"obj":"\"http://rdf.glycoinfo.org/glycan/G39143AQ\""},{"id":"GlycanIUPAC_T18","span":{"begin":477,"end":480},"obj":"\"http://rdf.glycoinfo.org/glycan/G39143AQ\""},{"id":"GlycanIUPAC_T19","span":{"begin":80,"end":83},"obj":"\"http://rdf.glycoinfo.org/glycan/G65149OO\""},{"id":"GlycanIUPAC_T20","span":{"begin":477,"end":480},"obj":"\"http://rdf.glycoinfo.org/glycan/G65149OO\""},{"id":"GlycanIUPAC_T21","span":{"begin":80,"end":83},"obj":"\"http://rdf.glycoinfo.org/glycan/G02766SY\""},{"id":"GlycanIUPAC_T22","span":{"begin":477,"end":480},"obj":"\"http://rdf.glycoinfo.org/glycan/G02766SY\""},{"id":"GlycanIUPAC_T23","span":{"begin":80,"end":83},"obj":"\"http://rdf.glycoinfo.org/glycan/G26019KJ\""},{"id":"GlycanIUPAC_T24","span":{"begin":477,"end":480},"obj":"\"http://rdf.glycoinfo.org/glycan/G26019KJ\""},{"id":"GlycanIUPAC_T25","span":{"begin":80,"end":83},"obj":"\"http://rdf.glycoinfo.org/glycan/G36429CZ\""},{"id":"GlycanIUPAC_T26","span":{"begin":477,"end":480},"obj":"\"http://rdf.glycoinfo.org/glycan/G36429CZ\""},{"id":"GlycanIUPAC_T27","span":{"begin":80,"end":83},"obj":"\"http://rdf.glycoinfo.org/glycan/G89633TP\""},{"id":"GlycanIUPAC_T28","span":{"begin":477,"end":480},"obj":"\"http://rdf.glycoinfo.org/glycan/G89633TP\""},{"id":"GlycanIUPAC_T29","span":{"begin":80,"end":83},"obj":"\"http://rdf.glycoinfo.org/glycan/G28494FO\""},{"id":"GlycanIUPAC_T30","span":{"begin":477,"end":480},"obj":"\"http://rdf.glycoinfo.org/glycan/G28494FO\""},{"id":"GlycanIUPAC_T31","span":{"begin":80,"end":83},"obj":"\"http://rdf.glycoinfo.org/glycan/G06219CP\""},{"id":"GlycanIUPAC_T32","span":{"begin":477,"end":480},"obj":"\"http://rdf.glycoinfo.org/glycan/G06219CP\""},{"id":"GlycanIUPAC_T33","span":{"begin":80,"end":83},"obj":"\"http://rdf.glycoinfo.org/glycan/G44237SM\""},{"id":"GlycanIUPAC_T34","span":{"begin":477,"end":480},"obj":"\"http://rdf.glycoinfo.org/glycan/G44237SM\""},{"id":"GlycanIUPAC_T35","span":{"begin":80,"end":83},"obj":"\"http://rdf.glycoinfo.org/glycan/G57948RL\""},{"id":"GlycanIUPAC_T36","span":{"begin":477,"end":480},"obj":"\"http://rdf.glycoinfo.org/glycan/G57948RL\""},{"id":"GlycanIUPAC_T37","span":{"begin":80,"end":83},"obj":"\"http://rdf.glycoinfo.org/glycan/G64016DN\""},{"id":"GlycanIUPAC_T38","span":{"begin":477,"end":480},"obj":"\"http://rdf.glycoinfo.org/glycan/G64016DN\""},{"id":"GlycanIUPAC_T39","span":{"begin":80,"end":83},"obj":"\"http://rdf.glycoinfo.org/glycan/G14536PC\""},{"id":"GlycanIUPAC_T40","span":{"begin":477,"end":480},"obj":"\"http://rdf.glycoinfo.org/glycan/G14536PC\""},{"id":"GlycanIUPAC_T41","span":{"begin":80,"end":83},"obj":"\"http://rdf.glycoinfo.org/glycan/G14356FW\""},{"id":"GlycanIUPAC_T42","span":{"begin":477,"end":480},"obj":"\"http://rdf.glycoinfo.org/glycan/G14356FW\""},{"id":"GlycanIUPAC_T43","span":{"begin":80,"end":83},"obj":"\"http://rdf.glycoinfo.org/glycan/G34565UO\""},{"id":"GlycanIUPAC_T44","span":{"begin":477,"end":480},"obj":"\"http://rdf.glycoinfo.org/glycan/G34565UO\""},{"id":"GlycanIUPAC_T45","span":{"begin":80,"end":83},"obj":"\"http://rdf.glycoinfo.org/glycan/G67124MW\""},{"id":"GlycanIUPAC_T46","span":{"begin":477,"end":480},"obj":"\"http://rdf.glycoinfo.org/glycan/G67124MW\""},{"id":"GlycanIUPAC_T47","span":{"begin":80,"end":83},"obj":"\"http://rdf.glycoinfo.org/glycan/G71457ZU\""},{"id":"GlycanIUPAC_T48","span":{"begin":477,"end":480},"obj":"\"http://rdf.glycoinfo.org/glycan/G71457ZU\""},{"id":"GlycanIUPAC_T49","span":{"begin":80,"end":83},"obj":"\"http://rdf.glycoinfo.org/glycan/G55228VZ\""},{"id":"GlycanIUPAC_T50","span":{"begin":477,"end":480},"obj":"\"http://rdf.glycoinfo.org/glycan/G55228VZ\""},{"id":"GlycanIUPAC_T51","span":{"begin":80,"end":83},"obj":"\"http://rdf.glycoinfo.org/glycan/G31034MJ\""},{"id":"GlycanIUPAC_T52","span":{"begin":477,"end":480},"obj":"\"http://rdf.glycoinfo.org/glycan/G31034MJ\""},{"id":"GlycanIUPAC_T53","span":{"begin":80,"end":83},"obj":"\"http://rdf.glycoinfo.org/glycan/G25776IP\""},{"id":"GlycanIUPAC_T54","span":{"begin":477,"end":480},"obj":"\"http://rdf.glycoinfo.org/glycan/G25776IP\""},{"id":"GlycanIUPAC_T55","span":{"begin":80,"end":83},"obj":"\"http://rdf.glycoinfo.org/glycan/G64442BV\""},{"id":"GlycanIUPAC_T56","span":{"begin":477,"end":480},"obj":"\"http://rdf.glycoinfo.org/glycan/G64442BV\""},{"id":"GlycanIUPAC_T57","span":{"begin":80,"end":83},"obj":"\"http://rdf.glycoinfo.org/glycan/G57018LE\""},{"id":"GlycanIUPAC_T58","span":{"begin":477,"end":480},"obj":"\"http://rdf.glycoinfo.org/glycan/G57018LE\""},{"id":"GlycanIUPAC_T59","span":{"begin":80,"end":83},"obj":"\"http://rdf.glycoinfo.org/glycan/G61761GX\""},{"id":"GlycanIUPAC_T60","span":{"begin":477,"end":480},"obj":"\"http://rdf.glycoinfo.org/glycan/G61761GX\""},{"id":"GlycanIUPAC_T61","span":{"begin":80,"end":83},"obj":"\"http://rdf.glycoinfo.org/glycan/G76318UX\""},{"id":"GlycanIUPAC_T62","span":{"begin":477,"end":480},"obj":"\"http://rdf.glycoinfo.org/glycan/G76318UX\""},{"id":"GlycanIUPAC_T63","span":{"begin":80,"end":83},"obj":"\"http://rdf.glycoinfo.org/glycan/G61906ER\""},{"id":"GlycanIUPAC_T64","span":{"begin":477,"end":480},"obj":"\"http://rdf.glycoinfo.org/glycan/G61906ER\""},{"id":"GlycanIUPAC_T65","span":{"begin":80,"end":83},"obj":"\"http://rdf.glycoinfo.org/glycan/G68723GR\""},{"id":"GlycanIUPAC_T66","span":{"begin":477,"end":480},"obj":"\"http://rdf.glycoinfo.org/glycan/G68723GR\""},{"id":"GlycanIUPAC_T67","span":{"begin":80,"end":83},"obj":"\"http://rdf.glycoinfo.org/glycan/G19540LE\""},{"id":"GlycanIUPAC_T68","span":{"begin":477,"end":480},"obj":"\"http://rdf.glycoinfo.org/glycan/G19540LE\""},{"id":"GlycanIUPAC_T69","span":{"begin":80,"end":83},"obj":"\"http://rdf.glycoinfo.org/glycan/G74944PO\""},{"id":"GlycanIUPAC_T70","span":{"begin":477,"end":480},"obj":"\"http://rdf.glycoinfo.org/glycan/G74944PO\""},{"id":"GlycanIUPAC_T71","span":{"begin":80,"end":83},"obj":"\"http://rdf.glycoinfo.org/glycan/G89489ZJ\""},{"id":"GlycanIUPAC_T72","span":{"begin":477,"end":480},"obj":"\"http://rdf.glycoinfo.org/glycan/G89489ZJ\""},{"id":"GlycanIUPAC_T73","span":{"begin":80,"end":83},"obj":"\"http://rdf.glycoinfo.org/glycan/G04434YU\""},{"id":"GlycanIUPAC_T74","span":{"begin":477,"end":480},"obj":"\"http://rdf.glycoinfo.org/glycan/G04434YU\""},{"id":"GlycanIUPAC_T75","span":{"begin":80,"end":83},"obj":"\"http://rdf.glycoinfo.org/glycan/G21450PB\""},{"id":"GlycanIUPAC_T76","span":{"begin":477,"end":480},"obj":"\"http://rdf.glycoinfo.org/glycan/G21450PB\""},{"id":"GlycanIUPAC_T77","span":{"begin":80,"end":83},"obj":"\"http://rdf.glycoinfo.org/glycan/G93629QY\""},{"id":"GlycanIUPAC_T78","span":{"begin":477,"end":480},"obj":"\"http://rdf.glycoinfo.org/glycan/G93629QY\""},{"id":"GlycanIUPAC_T79","span":{"begin":80,"end":83},"obj":"\"http://rdf.glycoinfo.org/glycan/G02603TR\""},{"id":"GlycanIUPAC_T80","span":{"begin":477,"end":480},"obj":"\"http://rdf.glycoinfo.org/glycan/G02603TR\""},{"id":"GlycanIUPAC_T81","span":{"begin":80,"end":83},"obj":"\"http://rdf.glycoinfo.org/glycan/G40280JP\""},{"id":"GlycanIUPAC_T82","span":{"begin":477,"end":480},"obj":"\"http://rdf.glycoinfo.org/glycan/G40280JP\""},{"id":"GlycanIUPAC_T83","span":{"begin":80,"end":83},"obj":"\"http://rdf.glycoinfo.org/glycan/G95259IC\""},{"id":"GlycanIUPAC_T84","span":{"begin":477,"end":480},"obj":"\"http://rdf.glycoinfo.org/glycan/G95259IC\""},{"id":"GlycanIUPAC_T85","span":{"begin":80,"end":83},"obj":"\"http://rdf.glycoinfo.org/glycan/G26900FE\""},{"id":"GlycanIUPAC_T86","span":{"begin":477,"end":480},"obj":"\"http://rdf.glycoinfo.org/glycan/G26900FE\""},{"id":"GlycanIUPAC_T87","span":{"begin":80,"end":83},"obj":"\"http://rdf.glycoinfo.org/glycan/G21346KK\""},{"id":"GlycanIUPAC_T88","span":{"begin":477,"end":480},"obj":"\"http://rdf.glycoinfo.org/glycan/G21346KK\""},{"id":"GlycanIUPAC_T89","span":{"begin":80,"end":83},"obj":"\"http://rdf.glycoinfo.org/glycan/G62509FF\""},{"id":"GlycanIUPAC_T90","span":{"begin":477,"end":480},"obj":"\"http://rdf.glycoinfo.org/glycan/G62509FF\""},{"id":"GlycanIUPAC_T91","span":{"begin":80,"end":83},"obj":"\"http://rdf.glycoinfo.org/glycan/G83932AK\""},{"id":"GlycanIUPAC_T92","span":{"begin":477,"end":480},"obj":"\"http://rdf.glycoinfo.org/glycan/G83932AK\""},{"id":"GlycanIUPAC_T93","span":{"begin":80,"end":83},"obj":"\"http://rdf.glycoinfo.org/glycan/G96978IB\""},{"id":"GlycanIUPAC_T94","span":{"begin":477,"end":480},"obj":"\"http://rdf.glycoinfo.org/glycan/G96978IB\""},{"id":"GlycanIUPAC_T95","span":{"begin":80,"end":83},"obj":"\"http://rdf.glycoinfo.org/glycan/G34275DN\""},{"id":"GlycanIUPAC_T96","span":{"begin":477,"end":480},"obj":"\"http://rdf.glycoinfo.org/glycan/G34275DN\""},{"id":"GlycanIUPAC_T97","span":{"begin":80,"end":83},"obj":"\"http://rdf.glycoinfo.org/glycan/G07071JF\""},{"id":"GlycanIUPAC_T98","span":{"begin":477,"end":480},"obj":"\"http://rdf.glycoinfo.org/glycan/G07071JF\""},{"id":"GlycanIUPAC_T99","span":{"begin":80,"end":83},"obj":"\"http://rdf.glycoinfo.org/glycan/G80639QD\""},{"id":"GlycanIUPAC_T100","span":{"begin":477,"end":480},"obj":"\"http://rdf.glycoinfo.org/glycan/G80639QD\""},{"id":"GlycanIUPAC_T101","span":{"begin":80,"end":83},"obj":"\"http://rdf.glycoinfo.org/glycan/G99460PJ\""},{"id":"GlycanIUPAC_T102","span":{"begin":477,"end":480},"obj":"\"http://rdf.glycoinfo.org/glycan/G99460PJ\""},{"id":"GlycanIUPAC_T103","span":{"begin":80,"end":83},"obj":"\"http://rdf.glycoinfo.org/glycan/G22024BZ\""},{"id":"GlycanIUPAC_T104","span":{"begin":477,"end":480},"obj":"\"http://rdf.glycoinfo.org/glycan/G22024BZ\""},{"id":"GlycanIUPAC_T105","span":{"begin":80,"end":83},"obj":"\"http://rdf.glycoinfo.org/glycan/G74097ZY\""},{"id":"GlycanIUPAC_T106","span":{"begin":477,"end":480},"obj":"\"http://rdf.glycoinfo.org/glycan/G74097ZY\""},{"id":"GlycanIUPAC_T107","span":{"begin":80,"end":83},"obj":"\"http://rdf.glycoinfo.org/glycan/G84439YP\""},{"id":"GlycanIUPAC_T108","span":{"begin":477,"end":480},"obj":"\"http://rdf.glycoinfo.org/glycan/G84439YP\""},{"id":"GlycanIUPAC_T109","span":{"begin":80,"end":83},"obj":"\"http://rdf.glycoinfo.org/glycan/G52207WQ\""},{"id":"GlycanIUPAC_T110","span":{"begin":477,"end":480},"obj":"\"http://rdf.glycoinfo.org/glycan/G52207WQ\""},{"id":"GlycanIUPAC_T111","span":{"begin":80,"end":83},"obj":"\"http://rdf.glycoinfo.org/glycan/G90695MS\""},{"id":"GlycanIUPAC_T112","span":{"begin":477,"end":480},"obj":"\"http://rdf.glycoinfo.org/glycan/G90695MS\""},{"id":"GlycanIUPAC_T113","span":{"begin":80,"end":83},"obj":"\"http://rdf.glycoinfo.org/glycan/G50398QX\""},{"id":"GlycanIUPAC_T114","span":{"begin":477,"end":480},"obj":"\"http://rdf.glycoinfo.org/glycan/G50398QX\""},{"id":"GlycanIUPAC_T115","span":{"begin":80,"end":83},"obj":"\"http://rdf.glycoinfo.org/glycan/G12166ZT\""},{"id":"GlycanIUPAC_T116","span":{"begin":477,"end":480},"obj":"\"http://rdf.glycoinfo.org/glycan/G12166ZT\""},{"id":"GlycanIUPAC_T117","span":{"begin":80,"end":83},"obj":"\"http://rdf.glycoinfo.org/glycan/G48368BR\""},{"id":"GlycanIUPAC_T118","span":{"begin":477,"end":480},"obj":"\"http://rdf.glycoinfo.org/glycan/G48368BR\""},{"id":"GlycanIUPAC_T119","span":{"begin":80,"end":83},"obj":"\"http://rdf.glycoinfo.org/glycan/G57407RW\""},{"id":"GlycanIUPAC_T120","span":{"begin":477,"end":480},"obj":"\"http://rdf.glycoinfo.org/glycan/G57407RW\""},{"id":"GlycanIUPAC_T121","span":{"begin":80,"end":83},"obj":"\"http://rdf.glycoinfo.org/glycan/G00386TY\""},{"id":"GlycanIUPAC_T122","span":{"begin":477,"end":480},"obj":"\"http://rdf.glycoinfo.org/glycan/G00386TY\""},{"id":"GlycanIUPAC_T123","span":{"begin":80,"end":83},"obj":"\"http://rdf.glycoinfo.org/glycan/G18723JK\""},{"id":"GlycanIUPAC_T124","span":{"begin":477,"end":480},"obj":"\"http://rdf.glycoinfo.org/glycan/G18723JK\""},{"id":"GlycanIUPAC_T125","span":{"begin":80,"end":83},"obj":"\"http://rdf.glycoinfo.org/glycan/G93757OR\""},{"id":"GlycanIUPAC_T126","span":{"begin":477,"end":480},"obj":"\"http://rdf.glycoinfo.org/glycan/G93757OR\""},{"id":"GlycanIUPAC_T127","span":{"begin":80,"end":83},"obj":"\"http://rdf.glycoinfo.org/glycan/G29006SI\""},{"id":"GlycanIUPAC_T128","span":{"begin":477,"end":480},"obj":"\"http://rdf.glycoinfo.org/glycan/G29006SI\""},{"id":"GlycanIUPAC_T129","span":{"begin":80,"end":83},"obj":"\"http://rdf.glycoinfo.org/glycan/G03099OQ\""},{"id":"GlycanIUPAC_T130","span":{"begin":477,"end":480},"obj":"\"http://rdf.glycoinfo.org/glycan/G03099OQ\""},{"id":"GlycanIUPAC_T131","span":{"begin":80,"end":83},"obj":"\"http://rdf.glycoinfo.org/glycan/G53739OW\""},{"id":"GlycanIUPAC_T132","span":{"begin":477,"end":480},"obj":"\"http://rdf.glycoinfo.org/glycan/G53739OW\""},{"id":"GlycanIUPAC_T133","span":{"begin":80,"end":83},"obj":"\"http://rdf.glycoinfo.org/glycan/G70440ZO\""},{"id":"GlycanIUPAC_T134","span":{"begin":477,"end":480},"obj":"\"http://rdf.glycoinfo.org/glycan/G70440ZO\""},{"id":"GlycanIUPAC_T135","span":{"begin":80,"end":83},"obj":"\"http://rdf.glycoinfo.org/glycan/G29951RR\""},{"id":"GlycanIUPAC_T136","span":{"begin":477,"end":480},"obj":"\"http://rdf.glycoinfo.org/glycan/G29951RR\""},{"id":"GlycanIUPAC_T137","span":{"begin":80,"end":83},"obj":"\"http://rdf.glycoinfo.org/glycan/G58402TI\""},{"id":"GlycanIUPAC_T138","span":{"begin":477,"end":480},"obj":"\"http://rdf.glycoinfo.org/glycan/G58402TI\""},{"id":"GlycanIUPAC_T139","span":{"begin":80,"end":83},"obj":"\"http://rdf.glycoinfo.org/glycan/G39875TP\""},{"id":"GlycanIUPAC_T140","span":{"begin":477,"end":480},"obj":"\"http://rdf.glycoinfo.org/glycan/G39875TP\""},{"id":"GlycanIUPAC_T141","span":{"begin":80,"end":83},"obj":"\"http://rdf.glycoinfo.org/glycan/G83439QV\""},{"id":"GlycanIUPAC_T142","span":{"begin":477,"end":480},"obj":"\"http://rdf.glycoinfo.org/glycan/G83439QV\""},{"id":"GlycanIUPAC_T143","span":{"begin":80,"end":83},"obj":"\"http://rdf.glycoinfo.org/glycan/G41762RC\""},{"id":"GlycanIUPAC_T144","span":{"begin":477,"end":480},"obj":"\"http://rdf.glycoinfo.org/glycan/G41762RC\""},{"id":"GlycanIUPAC_T145","span":{"begin":80,"end":83},"obj":"\"http://rdf.glycoinfo.org/glycan/G91604UI\""},{"id":"GlycanIUPAC_T146","span":{"begin":477,"end":480},"obj":"\"http://rdf.glycoinfo.org/glycan/G91604UI\""},{"id":"GlycanIUPAC_T147","span":{"begin":80,"end":83},"obj":"\"http://rdf.glycoinfo.org/glycan/G88447WE\""},{"id":"GlycanIUPAC_T148","span":{"begin":477,"end":480},"obj":"\"http://rdf.glycoinfo.org/glycan/G88447WE\""},{"id":"GlycanIUPAC_T149","span":{"begin":80,"end":83},"obj":"\"http://rdf.glycoinfo.org/glycan/G93634BS\""},{"id":"GlycanIUPAC_T150","span":{"begin":477,"end":480},"obj":"\"http://rdf.glycoinfo.org/glycan/G93634BS\""},{"id":"GlycanIUPAC_T151","span":{"begin":80,"end":83},"obj":"\"http://rdf.glycoinfo.org/glycan/G02587BH\""},{"id":"GlycanIUPAC_T152","span":{"begin":477,"end":480},"obj":"\"http://rdf.glycoinfo.org/glycan/G02587BH\""},{"id":"GlycanIUPAC_T153","span":{"begin":80,"end":83},"obj":"\"http://rdf.glycoinfo.org/glycan/G43511MX\""},{"id":"GlycanIUPAC_T154","span":{"begin":477,"end":480},"obj":"\"http://rdf.glycoinfo.org/glycan/G43511MX\""},{"id":"GlycanIUPAC_T155","span":{"begin":80,"end":83},"obj":"\"http://rdf.glycoinfo.org/glycan/G64958DH\""},{"id":"GlycanIUPAC_T156","span":{"begin":477,"end":480},"obj":"\"http://rdf.glycoinfo.org/glycan/G64958DH\""},{"id":"GlycanIUPAC_T157","span":{"begin":80,"end":83},"obj":"\"http://rdf.glycoinfo.org/glycan/G30384TR\""},{"id":"GlycanIUPAC_T158","span":{"begin":477,"end":480},"obj":"\"http://rdf.glycoinfo.org/glycan/G30384TR\""},{"id":"GlycanIUPAC_T159","span":{"begin":80,"end":83},"obj":"\"http://rdf.glycoinfo.org/glycan/G15624EX\""},{"id":"GlycanIUPAC_T160","span":{"begin":477,"end":480},"obj":"\"http://rdf.glycoinfo.org/glycan/G15624EX\""},{"id":"GlycanIUPAC_T161","span":{"begin":80,"end":83},"obj":"\"http://rdf.glycoinfo.org/glycan/G22706ST\""},{"id":"GlycanIUPAC_T162","span":{"begin":477,"end":480},"obj":"\"http://rdf.glycoinfo.org/glycan/G22706ST\""},{"id":"GlycanIUPAC_T163","span":{"begin":80,"end":83},"obj":"\"http://rdf.glycoinfo.org/glycan/G57408PI\""},{"id":"GlycanIUPAC_T164","span":{"begin":477,"end":480},"obj":"\"http://rdf.glycoinfo.org/glycan/G57408PI\""},{"id":"GlycanIUPAC_T165","span":{"begin":80,"end":83},"obj":"\"http://rdf.glycoinfo.org/glycan/G86403XX\""},{"id":"GlycanIUPAC_T166","span":{"begin":477,"end":480},"obj":"\"http://rdf.glycoinfo.org/glycan/G86403XX\""},{"id":"GlycanIUPAC_T167","span":{"begin":80,"end":83},"obj":"\"http://rdf.glycoinfo.org/glycan/G78043YB\""},{"id":"GlycanIUPAC_T168","span":{"begin":477,"end":480},"obj":"\"http://rdf.glycoinfo.org/glycan/G78043YB\""},{"id":"GlycanIUPAC_T169","span":{"begin":80,"end":83},"obj":"\"http://rdf.glycoinfo.org/glycan/G18952JK\""},{"id":"GlycanIUPAC_T170","span":{"begin":477,"end":480},"obj":"\"http://rdf.glycoinfo.org/glycan/G18952JK\""},{"id":"GlycanIUPAC_T171","span":{"begin":80,"end":83},"obj":"\"http://rdf.glycoinfo.org/glycan/G49020ND\""},{"id":"GlycanIUPAC_T172","span":{"begin":477,"end":480},"obj":"\"http://rdf.glycoinfo.org/glycan/G49020ND\""},{"id":"GlycanIUPAC_T173","span":{"begin":80,"end":83},"obj":"\"http://rdf.glycoinfo.org/glycan/G63590YW\""},{"id":"GlycanIUPAC_T174","span":{"begin":477,"end":480},"obj":"\"http://rdf.glycoinfo.org/glycan/G63590YW\""},{"id":"GlycanIUPAC_T175","span":{"begin":80,"end":83},"obj":"\"http://rdf.glycoinfo.org/glycan/G22793KS\""},{"id":"GlycanIUPAC_T176","span":{"begin":477,"end":480},"obj":"\"http://rdf.glycoinfo.org/glycan/G22793KS\""},{"id":"GlycanIUPAC_T177","span":{"begin":80,"end":83},"obj":"\"http://rdf.glycoinfo.org/glycan/G64134SS\""},{"id":"GlycanIUPAC_T178","span":{"begin":477,"end":480},"obj":"\"http://rdf.glycoinfo.org/glycan/G64134SS\""},{"id":"GlycanIUPAC_T179","span":{"begin":80,"end":83},"obj":"\"http://rdf.glycoinfo.org/glycan/G17338HY\""},{"id":"GlycanIUPAC_T180","span":{"begin":477,"end":480},"obj":"\"http://rdf.glycoinfo.org/glycan/G17338HY\""},{"id":"GlycanIUPAC_T181","span":{"begin":80,"end":83},"obj":"\"http://rdf.glycoinfo.org/glycan/G99745XF\""},{"id":"GlycanIUPAC_T182","span":{"begin":477,"end":480},"obj":"\"http://rdf.glycoinfo.org/glycan/G99745XF\""},{"id":"GlycanIUPAC_T183","span":{"begin":80,"end":83},"obj":"\"http://rdf.glycoinfo.org/glycan/G27782HN\""},{"id":"GlycanIUPAC_T184","span":{"begin":477,"end":480},"obj":"\"http://rdf.glycoinfo.org/glycan/G27782HN\""},{"id":"GlycanIUPAC_T185","span":{"begin":80,"end":83},"obj":"\"http://rdf.glycoinfo.org/glycan/G57496DC\""},{"id":"GlycanIUPAC_T186","span":{"begin":477,"end":480},"obj":"\"http://rdf.glycoinfo.org/glycan/G57496DC\""},{"id":"GlycanIUPAC_T187","span":{"begin":80,"end":83},"obj":"\"http://rdf.glycoinfo.org/glycan/G93169WB\""},{"id":"GlycanIUPAC_T188","span":{"begin":477,"end":480},"obj":"\"http://rdf.glycoinfo.org/glycan/G93169WB\""},{"id":"GlycanIUPAC_T189","span":{"begin":80,"end":83},"obj":"\"http://rdf.glycoinfo.org/glycan/G05518TD\""},{"id":"GlycanIUPAC_T190","span":{"begin":477,"end":480},"obj":"\"http://rdf.glycoinfo.org/glycan/G05518TD\""},{"id":"GlycanIUPAC_T191","span":{"begin":80,"end":83},"obj":"\"http://rdf.glycoinfo.org/glycan/G62603DN\""},{"id":"GlycanIUPAC_T192","span":{"begin":477,"end":480},"obj":"\"http://rdf.glycoinfo.org/glycan/G62603DN\""},{"id":"GlycanIUPAC_T193","span":{"begin":80,"end":83},"obj":"\"http://rdf.glycoinfo.org/glycan/G59574FS\""},{"id":"GlycanIUPAC_T194","span":{"begin":477,"end":480},"obj":"\"http://rdf.glycoinfo.org/glycan/G59574FS\""},{"id":"GlycanIUPAC_T195","span":{"begin":80,"end":83},"obj":"\"http://rdf.glycoinfo.org/glycan/G47567WC\""},{"id":"GlycanIUPAC_T196","span":{"begin":477,"end":480},"obj":"\"http://rdf.glycoinfo.org/glycan/G47567WC\""}],"text":"Increased fucosylation and reduced branching of serum glycoprotein N-glycans in all known subtypes of congenital disorder of glycosylation I.\nThe N-glycans present on the total mixture of serum glycoproteins (serum N-glycome) were analyzed in 24 subjects with congenital disorder of glycosylation type I (CDG-I) and 7 healthy, age-matched individuals. No new N-glycan structures were observed in the sera of CDG-I patients as compared with normal sera. However, we observed in all subtypes a significantly increased degree of core alpha-1,6-fucosylation of the biantennary glycans as compared to normal, as well as a significant decrease in the amount of triantennary glycans. These serum N-glycome changes appear to be a milder manifestation of some of the changes observed in adult liver cirrhosis patients, which is compatible with the reported steatosis and fibrosis in CDG-I patients. In the CDG-Ia subgroup, the extent of the serum N-glycome changes correlates with the aberration of the serum transferrin isoelectric focusing pattern, which measures the severity of the lack of entire N-glycan chains (primary consequence of CDG-I) in the liver and is the standard diagnostic test for this category of inherited diseases."}

{"project":"performance-test","denotations":[{"id":"PD-UBERON-AE-B_T1","span":{"begin":784,"end":789},"obj":"http://purl.obolibrary.org/obo/UBERON_0002107"},{"id":"PD-UBERON-AE-B_T2","span":{"begin":1146,"end":1151},"obj":"http://purl.obolibrary.org/obo/UBERON_0002107"},{"id":"PD-UBERON-AE-B_T3","span":{"begin":48,"end":53},"obj":"http://purl.obolibrary.org/obo/UBERON_0001977"},{"id":"PD-UBERON-AE-B_T4","span":{"begin":188,"end":193},"obj":"http://purl.obolibrary.org/obo/UBERON_0001977"},{"id":"PD-UBERON-AE-B_T5","span":{"begin":209,"end":214},"obj":"http://purl.obolibrary.org/obo/UBERON_0001977"},{"id":"PD-UBERON-AE-B_T6","span":{"begin":683,"end":688},"obj":"http://purl.obolibrary.org/obo/UBERON_0001977"},{"id":"PD-UBERON-AE-B_T7","span":{"begin":932,"end":937},"obj":"http://purl.obolibrary.org/obo/UBERON_0001977"},{"id":"PD-UBERON-AE-B_T8","span":{"begin":994,"end":999},"obj":"http://purl.obolibrary.org/obo/UBERON_0001977"}],"text":"Increased fucosylation and reduced branching of serum glycoprotein N-glycans in all known subtypes of congenital disorder of glycosylation I.\nThe N-glycans present on the total mixture of serum glycoproteins (serum N-glycome) were analyzed in 24 subjects with congenital disorder of glycosylation type I (CDG-I) and 7 healthy, age-matched individuals. No new N-glycan structures were observed in the sera of CDG-I patients as compared with normal sera. However, we observed in all subtypes a significantly increased degree of core alpha-1,6-fucosylation of the biantennary glycans as compared to normal, as well as a significant decrease in the amount of triantennary glycans. These serum N-glycome changes appear to be a milder manifestation of some of the changes observed in adult liver cirrhosis patients, which is compatible with the reported steatosis and fibrosis in CDG-I patients. In the CDG-Ia subgroup, the extent of the serum N-glycome changes correlates with the aberration of the serum transferrin isoelectric focusing pattern, which measures the severity of the lack of entire N-glycan chains (primary consequence of CDG-I) in the liver and is the standard diagnostic test for this category of inherited diseases."}

{"project":"mondo_disease","denotations":[{"id":"T1","span":{"begin":102,"end":138},"obj":"Disease"},{"id":"T2","span":{"begin":260,"end":303},"obj":"Disease"},{"id":"T3","span":{"begin":305,"end":308},"obj":"Disease"},{"id":"T4","span":{"begin":408,"end":411},"obj":"Disease"},{"id":"T5","span":{"begin":784,"end":799},"obj":"Disease"},{"id":"T6","span":{"begin":871,"end":877},"obj":"Disease"},{"id":"T7","span":{"begin":897,"end":903},"obj":"Disease"},{"id":"T8","span":{"begin":1132,"end":1135},"obj":"Disease"},{"id":"T9","span":{"begin":1209,"end":1227},"obj":"Disease"}],"attributes":[{"id":"A1","pred":"mondo_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/MONDO_0015286"},{"id":"A2","pred":"mondo_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/MONDO_0005500"},{"id":"A3","pred":"mondo_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/MONDO_0015286"},{"id":"A4","pred":"mondo_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/MONDO_0015286"},{"id":"A5","pred":"mondo_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/MONDO_0005155"},{"id":"A6","pred":"mondo_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/MONDO_0012783"},{"id":"A7","pred":"mondo_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/MONDO_0008907"},{"id":"A8","pred":"mondo_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/MONDO_0015286"},{"id":"A9","pred":"mondo_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/MONDO_0003847"}],"text":"Increased fucosylation and reduced branching of serum glycoprotein N-glycans in all known subtypes of congenital disorder of glycosylation I.\nThe N-glycans present on the total mixture of serum glycoproteins (serum N-glycome) were analyzed in 24 subjects with congenital disorder of glycosylation type I (CDG-I) and 7 healthy, age-matched individuals. No new N-glycan structures were observed in the sera of CDG-I patients as compared with normal sera. However, we observed in all subtypes a significantly increased degree of core alpha-1,6-fucosylation of the biantennary glycans as compared to normal, as well as a significant decrease in the amount of triantennary glycans. These serum N-glycome changes appear to be a milder manifestation of some of the changes observed in adult liver cirrhosis patients, which is compatible with the reported steatosis and fibrosis in CDG-I patients. In the CDG-Ia subgroup, the extent of the serum N-glycome changes correlates with the aberration of the serum transferrin isoelectric focusing pattern, which measures the severity of the lack of entire N-glycan chains (primary consequence of CDG-I) in the liver and is the standard diagnostic test for this category of inherited diseases."}

{"project":"HP-phenotype","denotations":[{"id":"T1","span":{"begin":784,"end":799},"obj":"Phenotype"},{"id":"T2","span":{"begin":848,"end":857},"obj":"Phenotype"}],"attributes":[{"id":"A1","pred":"hp_id","subj":"T1","obj":"HP:0001394"},{"id":"A2","pred":"hp_id","subj":"T2","obj":"HP:0001397"}],"namespaces":[{"prefix":"HP","uri":"http://purl.obolibrary.org/obo/HP_"}],"text":"Increased fucosylation and reduced branching of serum glycoprotein N-glycans in all known subtypes of congenital disorder of glycosylation I.\nThe N-glycans present on the total mixture of serum glycoproteins (serum N-glycome) were analyzed in 24 subjects with congenital disorder of glycosylation type I (CDG-I) and 7 healthy, age-matched individuals. No new N-glycan structures were observed in the sera of CDG-I patients as compared with normal sera. However, we observed in all subtypes a significantly increased degree of core alpha-1,6-fucosylation of the biantennary glycans as compared to normal, as well as a significant decrease in the amount of triantennary glycans. These serum N-glycome changes appear to be a milder manifestation of some of the changes observed in adult liver cirrhosis patients, which is compatible with the reported steatosis and fibrosis in CDG-I patients. In the CDG-Ia subgroup, the extent of the serum N-glycome changes correlates with the aberration of the serum transferrin isoelectric focusing pattern, which measures the severity of the lack of entire N-glycan chains (primary consequence of CDG-I) in the liver and is the standard diagnostic test for this category of inherited diseases."}

{"project":"Anatomy-UBERON","denotations":[{"id":"T1","span":{"begin":784,"end":789},"obj":"Body_part"},{"id":"T2","span":{"begin":1146,"end":1151},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"uberon_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/UBERON_0002107"},{"id":"A2","pred":"uberon_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/UBERON_0002107"}],"text":"Increased fucosylation and reduced branching of serum glycoprotein N-glycans in all known subtypes of congenital disorder of glycosylation I.\nThe N-glycans present on the total mixture of serum glycoproteins (serum N-glycome) were analyzed in 24 subjects with congenital disorder of glycosylation type I (CDG-I) and 7 healthy, age-matched individuals. No new N-glycan structures were observed in the sera of CDG-I patients as compared with normal sera. However, we observed in all subtypes a significantly increased degree of core alpha-1,6-fucosylation of the biantennary glycans as compared to normal, as well as a significant decrease in the amount of triantennary glycans. These serum N-glycome changes appear to be a milder manifestation of some of the changes observed in adult liver cirrhosis patients, which is compatible with the reported steatosis and fibrosis in CDG-I patients. In the CDG-Ia subgroup, the extent of the serum N-glycome changes correlates with the aberration of the serum transferrin isoelectric focusing pattern, which measures the severity of the lack of entire N-glycan chains (primary consequence of CDG-I) in the liver and is the standard diagnostic test for this category of inherited diseases."}

{"project":"Anatomy-MAT","denotations":[{"id":"T1","span":{"begin":784,"end":789},"obj":"Body_part"},{"id":"T2","span":{"begin":1146,"end":1151},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"mat_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/MAT_0000097"},{"id":"A2","pred":"mat_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/MAT_0000097"}],"text":"Increased fucosylation and reduced branching of serum glycoprotein N-glycans in all known subtypes of congenital disorder of glycosylation I.\nThe N-glycans present on the total mixture of serum glycoproteins (serum N-glycome) were analyzed in 24 subjects with congenital disorder of glycosylation type I (CDG-I) and 7 healthy, age-matched individuals. No new N-glycan structures were observed in the sera of CDG-I patients as compared with normal sera. However, we observed in all subtypes a significantly increased degree of core alpha-1,6-fucosylation of the biantennary glycans as compared to normal, as well as a significant decrease in the amount of triantennary glycans. These serum N-glycome changes appear to be a milder manifestation of some of the changes observed in adult liver cirrhosis patients, which is compatible with the reported steatosis and fibrosis in CDG-I patients. In the CDG-Ia subgroup, the extent of the serum N-glycome changes correlates with the aberration of the serum transferrin isoelectric focusing pattern, which measures the severity of the lack of entire N-glycan chains (primary consequence of CDG-I) in the liver and is the standard diagnostic test for this category of inherited diseases."}

{"project":"CL-cell","denotations":[{"id":"T1","span":{"begin":297,"end":303},"obj":"Cell"}],"attributes":[{"id":"A1","pred":"cl_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/CL:0004120"},{"id":"A2","pred":"cl_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/CL:0004138"}],"text":"Increased fucosylation and reduced branching of serum glycoprotein N-glycans in all known subtypes of congenital disorder of glycosylation I.\nThe N-glycans present on the total mixture of serum glycoproteins (serum N-glycome) were analyzed in 24 subjects with congenital disorder of glycosylation type I (CDG-I) and 7 healthy, age-matched individuals. No new N-glycan structures were observed in the sera of CDG-I patients as compared with normal sera. However, we observed in all subtypes a significantly increased degree of core alpha-1,6-fucosylation of the biantennary glycans as compared to normal, as well as a significant decrease in the amount of triantennary glycans. These serum N-glycome changes appear to be a milder manifestation of some of the changes observed in adult liver cirrhosis patients, which is compatible with the reported steatosis and fibrosis in CDG-I patients. In the CDG-Ia subgroup, the extent of the serum N-glycome changes correlates with the aberration of the serum transferrin isoelectric focusing pattern, which measures the severity of the lack of entire N-glycan chains (primary consequence of CDG-I) in the liver and is the standard diagnostic test for this category of inherited diseases."}